Detalles de la búsqueda
1.
The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Final patient-reported outcomes at 24 months.
Diabetes Obes Metab
; 25(12): 3453-3464, 2023 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-37712754
2.
The real-world observational prospective study of health outcomes with dulaglutide and liraglutide in patients with type 2 diabetes (TROPHIES): Final, 24-month analysis of time to first significant treatment change, treatment persistence and clinical outcomes.
Diabetes Obes Metab
; 25(12): 3465-3477, 2023 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-37700627
3.
Estimating meaningful change for The Impact of Weight on Self-Perception (IW-SP) questionnaire among people with type 2 diabetes.
Qual Life Res
; 32(12): 3359-3371, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37491582
4.
Efficacy and Safety of Tirzepatide in Adults With Type 2 Diabetes: A Perspective for Primary Care Providers.
Clin Diabetes
; 41(2): 258-272, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37092144
5.
Type 2 diabetes pharmacotherapy trends in high-risk subgroups.
Diabetes Obes Metab
; 24(6): 1166-1171, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35243741
6.
The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Patients with Type 2 Diabetes (TROPHIES): Patient disposition, clinical characteristics and treatment persistence at 12 months.
Diabetes Obes Metab
; 24(12): 2373-2382, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-35876235
7.
Patients' preferences for once-daily oral versus once-weekly injectable diabetes medications: The REVISE study.
Diabetes Obes Metab
; 23(2): 508-519, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33140575
8.
Health state utilities associated with treatment process for oral and injectable GLP-1 receptor agonists for type 2 diabetes.
Qual Life Res
; 30(7): 2033-2043, 2021 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-33886044
9.
Assessing patient PREFERence between the dulaglutide pen and the semaglutide pen: A crossover study (PREFER).
Diabetes Obes Metab
; 22(3): 355-364, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-31646727
10.
Generalizability of glucagon-like peptide-1 receptor agonist cardiovascular outcome trials to the overall type 2 diabetes population in the United States.
Diabetes Obes Metab
; 21(6): 1299-1304, 2019 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-30714309
11.
United States Valuation of EQ-5D-5L Health States Using an International Protocol.
Value Health
; 22(8): 931-941, 2019 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-31426935
12.
The Prime Diabetes Model: Novel Methods for Estimating Long-Term Clinical and Cost Outcomes in Type 1 Diabetes Mellitus.
Value Health
; 20(7): 985-991, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-28712629
13.
Evaluation of the impact of once weekly dulaglutide on patient-reported outcomes in Japanese patients with type 2 diabetes: comparisons with liraglutide, insulin glargine, and placebo in two randomized studies.
Health Qual Life Outcomes
; 15(1): 123, 2017 Jun 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-28606095
14.
Health state utilities associated with attributes of weekly injection devices for treatment of type 2 diabetes.
BMC Health Serv Res
; 17(1): 774, 2017 Nov 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-29178918
15.
A qualitative examination of the content validity of the EQ-5D-5L in patients with type 2 diabetes.
Health Qual Life Outcomes
; 13: 192, 2015 Dec 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-26627874
16.
Impact of caregiver and parenting status on time trade-off and standard gamble utility scores for health state descriptions.
Health Qual Life Outcomes
; 12: 48, 2014 Apr 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-24716709
17.
Utilities for Complications Associated with Type 2 Diabetes: A Review of the Literature.
Adv Ther
; 2024 May 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-38771477
18.
An Economic Evaluation of the Relationship Between Glycemic Control and Total Healthcare Costs for Adults with Type 2 Diabetes: Retrospective Cohort Study.
Diabetes Ther
; 15(2): 395-407, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38038897
19.
Physician Perceptions of Dose Escalation for Type 2 Diabetes Medications in the United States.
Diabetes Ther
; 15(2): 381-393, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-37979125
20.
Health state utilities associated with weight loss: preferences of people with type 2 diabetes and obesity in Japan.
J Med Econ
; 27(1): 370-380, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38347819